BioNTech strategy chief Richardson to leave for 'new professional opportunities'
BioNTech's strategy chief Ryan Richardson is exiting the German company on Sept. 30 "to pursue new professional opportunities," the infectious disease and cancer drug developer said Thursday. His...
View ArticleMassive proteomics study reveals new clues about Alzheimer’s and rekindles...
Amyloid plaques and tau tangles are the most well-known protein structures associated with Alzheimer’s, but a new study bolsters the longstanding notion that there’s a lot more going on in the disease....
View ArticleThermo Fisher buys Sanofi factory; Amphastar Pharma quadruples HQ capacity
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Thermo Fisher Scientific is acquiring a fill-finish and packaging...
View Article#IAS25: Q&A with International AIDS Society leader on HIV funding,...
KIGALI, RWANDA — Four decades into the HIV epidemic, the significance of conferences can easily be forgotten. But the International AIDS Society’s meeting on HIV Science this week in Rwanda will likely...
View ArticleUK government pledges “billions of pounds” for new research center in Essex
In its next move to boost the life sciences industry, the UK government is earmarking at least £250 million ($335 million) to help build a new research and development site called the National...
View ArticleNicox, Kowa make a deal for glaucoma drug; French techbio raises €15M
Plus, news about Clearside Biomedical: Nicox, Kowa ink licensing deal worth up to €191.5M: Kowa is gaining the exclusive rights to an experimental glaucoma treatment called NCX 470 in the US ...
View ArticleA health system takes an Amazon-like approach
Last week, Chicago-based Rush University System for Health debuted "Rush Connect," a subscription service that puts it toe to toe with other direct-to-consumer companies vying to be the first place ...
View ArticleBristol Myers, Pfizer launch DTC offering for Eliquis at 40% discount
Bristol Myers Squibb and Pfizer have announced a direct-to-consumer offering for their megablockbuster blood thinner Eliquis, marking a voluntary effort to lower drug prices amid the threat of...
View ArticlePharmaceutical exports from Ireland climb again as tariffs inch closer
New data from Ireland’s Central Statistics Office suggest that pharmaceutical companies are exporting more inventory to the US as the threat of drug tariffs persists. Medical and pharmaceutical product...
View ArticleFDA adcomm votes against GSK’s Blenrep in multiple myeloma
The FDA’s Oncologic Drugs Advisory Committee on Thursday voted 5-3 against the overall benefit-risk of GSK’s Blenrep as a second-line multiple myeloma treatment in combination with bortezomib and...
View ArticleThree takeaways from US senators’ report on pharma-telehealth relationships
Eli Lilly and Pfizer launched new services last year meant to give patients easier access to clinicians who can prescribe their drugs. The direct-to-consumer sites, called LillyDirect and PfizerForAll,...
View ArticleSarepta patient dies in study for limb-girdle muscular dystrophy, raising...
Sarepta Therapeutics said that a patient died in a clinical trial testing one of its gene therapies for limb-girdle muscular dystrophy, the latest death for a company that's already under heightened...
View ArticleBill Anderson to stay on at Bayer; C-suite changes at troubled Sarepta
Lots to recap this week for Peer Review! → Bayer CEO Bill Anderson has been given at least three more years at the German pharma and agriculture conglomerate. Since joining in 2023 ...
View Article#IAS25: HIV activists, scientists press for change, fueled by excitement for...
KIGALI, RWANDA — Emotions ran high this week at one of the world’s leading HIV science conferences after months of adapting in real-time to funding pullbacks that have shuttered or stalled critical HIV...
View ArticleViatris’ ophthalmic drug flunks Phase 3 study, company mulls next steps
Viatris said Friday its treatment candidate for a common form of eye inflammation failed a late-stage trial, casting uncertainty on the program’s future. The biotech’s pimecrolimus 0.3% ointment did...
View ArticleBristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint...
Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were...
View ArticleDavid Baker’s lab uses AI to help catch nature’s squirmiest proteins
In the wide world of traditionally undruggable proteins, one group stands out as the trickiest to catch. These squiggly molecules seem to have no stable structure, and their squirminess makes capturing...
View ArticleFDA will ask Sarepta to stop selling Duchenne treatment, following patient...
The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company's hopes for the product following two...
View ArticleFDA rejects expanded label for Roche's Columvi
The FDA issued a complete response letter to Roche’s Columvi, saying the data that the company provided for the label expansion aren't sufficient. Roche’s Genentech had been seeking approval for...
View ArticlePeter Marks says Sarepta gene therapy pause 'makes sense'
Former CBER chief Peter Marks says that a decision to pause shipments of Sarepta’s gene therapy for Duchenne muscular dystrophy “makes sense at this time,” and that there could be broader issues with...
View ArticleSail Bio cuts staff by 30% and trims leadership team
Sail Biomedicines, a well-funded startup that once aspired to become Moderna 2.0, is downsizing as it tries to get its lead program — an in vivo CAR-T cell therapy for autoimmune disease — into the...
View ArticleFDA adcomm votes against Otsuka's Rexulti-Zoloft combo for PTSD
The FDA’s Psychopharmacologic Drugs Advisory Committee on Friday voted 10-1 against the combination of Otsuka’s Rexulti and the antidepressant Zoloft, raising concerns about a failed Phase 3 clinical...
View ArticleSarepta says it won't pull Duchenne gene therapy, setting up showdown with FDA
Sarepta Therapeutics said it won't comply with an FDA request to stop shipping the company's treatment for Duchenne muscular dystrophy, following two patient deaths, likely setting up a high-profile...
View ArticleSarepta’s crisis week; Prasad overrides reviewers again; A new study’s clues...
Welcome back to another edition of Endpoints Weekly! I’m flying solo this week as my recap partner Nicole DeFeudis is on vacation for her wedding! I can speak for all of us here at Endpoints ...
View Article
